secwatch.observer — SEC 8-K summary
======================================

Issuer:     Voyager Therapeutics, Inc. (VYGR)
CIK:        0001640266
Form:       8-K
Filed at:   2026-08-06T20:03:23+00:00
Accession:  0001640266-26-000007
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Voyager Q2 net loss narrows to $24.5M; cash $148.8M, runway into 2028; tau programs on track for Q4 data
--------------------------------------------------------------------------------

- Net loss $24.5M in Q2 2026 vs $33.4M in Q2 2025; collaboration revenue $3.2M (down from $5.2M).
- Cash, equivalents, and marketable securities $148.8M as of June 30, 2026; expected to fund operations into 2028.
- VY7523 tau PET imaging data expected Q4 2026; VY1706 tau gene therapy IND cleared, dosing expected Q4 2026.
- Neurocrine partner intends to initiate NBIB-223 trial for Friedreich's ataxia in H2 2026 pending FDA IND clearance.
- R&D expenses $22.0M (down from $31.3M) and G&A $7.5M (down from $10.5M) due to prioritization and restructuring.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1640266/000164026626000007/0001640266-26-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1640266/000164026626000007/vygr-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001640266-26-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer